Press Releases

06.14.2016

Shire to License PF-00547659 from Pfizer, Adding to Established and Leading Gastrointestinal Portfolio

06.12.2016

Pfizer Announces Final Results from Inotuzumab Ozogamicin Pivotal Phase 3 Study in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

06.11.2016

Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes

06.09.2016

Pro Golfer Jim Furyk Teams Up With Pfizer To Raise Awareness For Pneumococcal Pneumonia And The Importance Of Older Adult Vaccination

06.08.2016

Pfizer Announces FDA Advisory Committees’ Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval

06.08.2016

Pfizer Research Advances Body Of Evidence For Tofacitinib Citrate (XELJANZ®) Providing Clinicians With Additional Information For The Treatment Of Moderate to Severe RA

06.07.2016

A Mother’s Mission to Help Prevent Another Life Lost to MenB

06.07.2016

Pfizer Announces Positive Top-Line Results from Second Phase 3 Trial of Oral XELJANZ® (Tofacitinib Citrate) in Adults with Psoriatic Arthritis

06.06.2016

ASCO 2016: Pivotal Avelumab Study Shows Positive Results in Metastatic Merkel Cell Carcinoma

06.06.2016

Pfizer Presents Promising Data from Next Generation ALK/ROS1 Inhibitor in Advanced Non-Small Cell Lung Cancer

06.05.2016

Weizmann Institute of Science Announces Visiting Scientist Agreement with Pfizer Inc.

06.04.2016

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor